Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data
M Kushnir, Y Choi, R Eisenberg, D Rao… - The Lancet …, 2019 - thelancet.com
Background Because studies of direct oral anticoagulants in patients with venous
thromboembolism and non-valvular atrial fibrillation have had minimal representation of …
thromboembolism and non-valvular atrial fibrillation have had minimal representation of …
Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients
C Kalani, E Awudi, T Alexander, G Udeani… - Hospital …, 2019 - Taylor & Francis
Purpose: There is limited clinical data evaluating anticoagulation with the direct oral
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …
anticoagulants (DOACs) in morbidly obese patients. We sought to examine the efficacy in …
Comparative effectiveness and safety of direct oral anticoagulants in obese patients with atrial fibrillation
Background Unlike warfarin direct oral anticoagulants (DOACs) are administered in fixed
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
doses, which raises concerns of its effectiveness on larger patients. Data from randomized …
Meta-analysis comparing direct oral anticoagulants versus warfarin in morbidly obese patients with atrial fibrillation
K Kido, M Shimizu, T Shiga, M Hashiguchi - The American journal of …, 2020 - Elsevier
Highlights•Direct oral anticoagulants did not increase stroke or systemic embolism event
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …
rate.•Direct oral anticoagulants had lower major bleeding rate than warfarin.•Direct oral …
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or …
AR Novak, C Shakowski, TC Trujillo, GC Wright… - Journal of Thrombosis …, 2022 - Springer
Despite evolving evidence, the use of direct oral anticoagulants (DOACs) in patients with
extremes of body weight remains controversial. This study aimed to measure the impact of …
extremes of body weight remains controversial. This study aimed to measure the impact of …
Direct oral anticoagulants versus warfarin in morbidly obese patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis
Background: Direct oral anticoagulants (DOACs) have been increasingly preferred over
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …
warfarin; however, The International Society of Thrombosis and Hemostasis recommended …
Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
CP O'Kane, JCO Avalon, JL Lacoste… - … : The Journal of …, 2022 - Wiley Online Library
Background Apixaban and rivaroxaban are increasingly used for thromboembolism
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …
prophylaxis in patients with non‐valvular atrial fibrillation (NVAF) and commonly in patients …
Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: a systematic review with meta-analysis
V Mai, E Marceau-Ferron, L Bertoletti, Y Lacasse… - Pharmacological …, 2021 - Elsevier
Background Direct oral anticoagulants'(DOAC) pharmacokinetics are affected by obesity.
Their efficacy and safety in obesity (BMI≥ 30 kg/m 2) and morbid obesity (BMI≥ 40 kg/m 2) …
Their efficacy and safety in obesity (BMI≥ 30 kg/m 2) and morbid obesity (BMI≥ 40 kg/m 2) …
[HTML][HTML] Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and …
Essentials• The association of body weight and patient‐important outcomes remains
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …
unknown.• Phase III randomized controlled trials of direct oral anticoagulants (DOACs) were …